Topic: Health

Researchers found that many people with type 2 diabetes stop taking GLP-1 medications within a year or two. However, most of them restart the treatment later.

Scientists studied over 60,000 Americans with type 2 diabetes who were taking GLP-1 medications. They wanted to know how many people stopped taking these medicines and why. The team found that about 4 in 10 patients stopped their medication within a year, and nearly 6 in 10 had stopped by the end of two years.

The researchers also discovered that more than half of those who stopped taking the medicine restarted it within a year, and nearly two-thirds did so within two years. This suggests that for many people, these medications aren't being abandoned permanently; use is more start-and-stop than most people assumed.

The study looked at various factors to understand what influences treatment patterns. They found that people covered by Medicaid or Medicare, Black patients, and those who experienced nausea or other gastrointestinal side effects were more likely to stop taking the medication within a year. On the other hand, patients whose first prescription came from an endocrinologist were 10% less likely to stop treatment.

The type of GLP-1 drug also made a difference. People taking newer drugs like tirzepatide were 41% less likely to discontinue treatment than those using older medications like liraglutide. Users of semaglutide were 28% less likely to discontinue anti-obesity medication use compared with people taking older drugs.

The study's findings are important because consistent use of these medications is what produces their protective effects. Stopping early may mean missed opportunities to prevent heart attacks, kidney disease progression, and other complications.

Why It Matters

This research matters because it highlights the importance of consistent treatment for people with type 2 diabetes. As India struggles with a growing diabetes epidemic, understanding how patients respond to medication can help healthcare providers develop more effective treatment plans.

Key Facts

• About 4 in 10 patients stopped their GLP-1 medication within a year
• Nearly 6 in 10 had stopped by the end of two years
• More than half of those who stopped restarted therapy within a year (41.5%)
• Newer GLP-1 drugs like tirzepatide were 41% less likely to discontinue treatment
• Patients whose first prescription came from an endocrinologist were 10% less likely to stop treatment

Key Terms

GLP-1

A type of medication used to treat type 2 diabetes

Implications

This research matters because it highlights the importance of consistent treatment for people with type 2 diabetes. As India struggles with a growing diabetes epidemic, understanding how patients respond to medication can help healthcare providers develop more effective treatment plans.